

Elections to Council Nucleus and Nominating committee 2024-2026

Motivation letter: Why are you interested in joining the Council Nucleus or Nominating committee (250 words max)?

Dear prof. Lyon and prof. Lopez,

With this letter I would like to apply for the position of president-elect of the Council of CardioOncology for the period of 2024-2026.

The care for patients suffering from cardiac disease is my driving force. It is my sincere belief that, through solid research, better education and improving organization, we can increase life expectancy and quality of life of our patients. I work as a clinical cardiologist with expertise in acute heart failure and I am responsible for the cardio-oncology clinic.


My research interests are translational science with topics that bridge the gap between bench and bedside. We focus on understanding the susceptibility to develop heart failure especially focusing on cardiotoxic treatments. For example, I'm currently holding an ERC Consolidator grant to study the susceptibility and resilience to develop heart failure after anthracycline treatment.

I have been a nucleus member of the Council of Cardio-Oncology of the ESC and focused on the educational program. I was course-director of a webinar on amyloidosis, which was well-received. In addition, I was involved in the writing of a position paper on acute cardio-toxicity. From 2022 I have been secretary of the council. Furthermore, I serve as editorial board member of JACC-Cardio-Oncology and member of the Dutch working group on cardio-oncology.

Thank you for the opportunity to apply for an extension of my membership of the Council of Cardio-Oncology.

• **PERSONAL INFORMATION**

Family name, First name:	VAN DER MEER, PETER
--------------------------	----------------------------



• **CURRENT POSITION**

Current position	Full Professor of Cardiology / physician-scientist/ cardiologist. Chair Experimental Cardiology, Dept. Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands
-------------------------	---

Place of work.	
Institute/organisation:	University Medical Center Groningen
Department:	Cardiology
Address:	Hanzeplein 1
Post code / Zip:	9700 RB GRONINGEN
Country:	The Netherlands

General Curriculum Vitae
<ul style="list-style-type: none"> • Prof. dr. Peter van der Meer received both his MD and PhD cum laude from the University of Groningen in the Netherlands. • He did a post-doctoral fellowship at Harvard where he identified new cardiac progenitor cells and established a platform for cell delivery in cardiac regenerative medicine for which he holds a patent. The results of this work were published in Science, awarded by the AHA as one of the top 10 papers in 2009, and for which he received an ACC Young Investigator Award. • After returning to the Netherlands he became staff cardiologist at the University Medical Center Groningen and initiated his own research group. Ever since, 30 PhD students have finished their theses under his supervision and many of them became cardiologists and/or (assistant) professors to start their own research groups. • He received numerous grants, including the prestigious European Research Council (ERC) Starting Grant (€1.5Mio) and ERC consolidator Grant (€2Mio) • His research group consists of PhD students, post-docs and technicians from many nationalities with various backgrounds (biologists, medical doctors, and biomedical-engineers) working on translational topics to bridge the gap between bench and bedside. His group focuses on understanding the susceptibility to develop heart failure and exploring novel treatment targets and therapies. • He has authored >300 publications and his H-factor is 89. • He is a member of several steering committees of large trials investigating the impact of new and old drugs, including digoxin(co-PI), iron therapy, sacubitril-valsartan, selenium/coQ10(PI), SGLT2i and potassium binders. • He is a consultant cardiologist of the National Amyloidosis Center Groningen and responsible for the cardio-oncology clinic. • He is full professor in cardiology and staff cardiologist, member of the LVAD and Heart Transplantation Team and currently chair of the department experimental cardiology of the UMCG. • Van der Meer was a member of the 2016 ESC HF guidelines writing committee and reviewer of the updated 2023 HF guidelines. • He was voted by his peers as treasurer (2020-2022) and secretary (2022-2024) of the ESC Council of Cardio-Oncology. • He was member of the writing committee of the 2022 ESC guidelines on Cardio-Oncology.

SELECTED PUBLICATIONS

- Hoes MF,..., **Van der Meer P**. Human iPSC-derived cardiomyocytes of peripartum cardiomyopathy patients reveal aberrant regulation of lipid metabolism. *Circulation* 2020;142:2288–2291.
- Vermeer MC,... , **Van der Meer P**. Gain-of-function mutation in KLHL24 causes desmin degradation and dilatation in hiPSC- derived engineered heart tissues.. *J Clin Invest*. 2021;131(17):e140615.
- Grote Beverborg N, ...**Van der Meer P**. Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy.. *Nat Commun*. 2021;12(1):5180.
- Tromp J, , **van der Meer P** Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls.. *Eur J Heart Fail*. 2020;22:1239-1246
- Linders AN, Braga Dias I, ... **Van der Meer P**. Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart Tissues. *J Am Coll Cardiol CardioOnc*. 2023;5:298–315
- Garcia, ...**Van der Meer P**,... Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. *N Engl J Med*. 2023.
- Tromp J, ...**Van der Meer P**. Novel endotypes in HF: effects on guideline-directed medical therapy. *Eur Heart J* 2018;39:4269–4276.
- Ter Maaten JM, Beldhuis IE, **van der Meer P et al**. Natriuresis-guided diuretic therapy in acute HF: a pragmatic randomized trial.. *Nat Med*. 2023
- Kosiborod MN,....**Van der Meer P**,.... Semaglutide in Patients with HFpEF and Obesity. *N Engl J Med*. 2023
- Markousis-Mavrogenis, ...**Van der Meer P**. Immunomodulation and immunopharmacology in heart failure. *Nat Rev Cardiol*. 2024;119-149